technology
Commented by André Will-Laudien on October 22nd, 2026 | 05:48 CEST
NATO Steps Up - Defence Stocks In Focus: Dassault Aviation, OHB, HPQ Silicon and DroneShield
Created and published on behalf of HPQ Silicon
The foiled drone attack in Leipzig provided an initial wake-up call for Western NATO partners regarding the threat situation in Europe. Alongside intra-European cooperation, closer ties with Canada in the defence and raw materials industries are also coming to the fore. The latest talks point to decisions with strategic, economic and geopolitical implications, setting a pioneering framework for the coming years. Enhanced transatlantic cooperation combines European expertise with Canada's vast wealth of resources to sustainably strengthen joint defence capabilities. By gaining direct access to key deposits, Europe is reducing its risky dependence on raw materials from autocratic states such as China and third countries. Canada has many of the 34 raw materials the EU has classified as critical, including essential lithium, nickel, cobalt and copper. These metals form the indispensable foundation for modern military technologies such as electronic components, engines and highly sensitive communication systems. To underpin this bilateral bridge, the governments and institutions involved have approved enormous budgets and framework agreements for the coming years. The European SAFE programme for rearmament and defence procurement therefore has an initial volume of EUR 150 billion, with subsequent expansions subject to further decisions. For investors, this set-up provides a good basis for portfolio gains. We delve a little deeper.
Read
Commented by Stefan Feulner on October 22nd, 2026 | 05:25 CEST
BioNTech, Formycon, Biogen: Pharma billions are being redistributed
The pharmaceutical industry is facing a massive restructuring. As blockbuster drugs worth billions lose patent exclusivity, cheaper copycat products are entering the market. At the same time, biotech groups are investing billions in new cancer drugs and therapies for diseases that have long been difficult to treat. For investors, this creates tension between established revenue generators, new active ingredients and rising healthcare costs. Companies that secure access to lucrative drug markets early are particularly interesting. Even a small share of a global blockbuster's revenue can have considerable economic significance.
Read
Commented by Stefan Feulner on October 21st, 2026 | 05:38 CEST
Regeneron, Vidac Pharma, Krystal Biotech: New Active Ingredients, Enormous Stock Market Potential
Cancer treatment is undergoing a fundamental transformation. Rather than relying solely on conventional chemotherapy, new approaches increasingly target the biological mechanisms that drive tumours. In particular, immunotherapies, gene therapies and interventions targeting cellular metabolism are opening up new possibilities for treating skin cancer. As approved medicines reach more patients, innovative biotech companies face key clinical milestones. Commercial opportunities are substantial, as demand for effective, well-tolerated treatments continues to grow. The decisive factor will be which technologies can confirm their promising results in larger clinical trials.
Read
Commented by Fabian Lorenz on October 20th, 2026 | 05:26 CEST
Nordex and Aixtron Start Rally! Desert Gold shares With A Buy Recommendation!
Created and Published on Behalf of Desert Gold Ventures Inc.
Are Nordex and Aixtron shares finally taking off again? Both companies impressed the stock market with their preliminary results last week. Although both shares remain in a downtrend, their operational performance remains solid. The Underperform rating for Nordex should not be overinterpreted. Another potential candidate for a year-end rally is Desert Gold. Its investment case is largely independent of the gold price. Analysts see significant upside potential and rate the shares a Buy. The reason: Desert Gold is expected to become a gold producer before the end of this year.
Read
Commented by Stefan Feulner on October 20th, 2026 | 05:23 CEST
AstraZeneca, Cardiol Therapeutics, Kiniksa – New hope for heart patients
Cardiovascular diseases remain among the greatest medical challenges worldwide. While established pharmaceutical groups invest billions in new active ingredients and artificial intelligence, specialised biotech companies are developing targeted therapies for conditions that have so far been difficult to treat, such as recurrent pericarditis. Patients often suffer from painful relapses and require long-term treatment. New medicines could fundamentally change how these conditions are managed. For investors, this brings into focus companies that already market approved products or are awaiting pivotal clinical trial results.
Read
Commented by Fabian Lorenz on October 19th, 2026 | 05:35 CEST
Up 38% in One Week: OHB Takes Off - Could Nel ASA and First Hydrogen Be Next?
What a week for OHB shares. The stock surged by around 38%. This could mark the end of the sharp correction. Analysts see further upside for the German space company, citing its strong order backlog, which could expand further soon. Beyond space, robotics is another market of the future. Leading investment banks predict golden times for the sector. First Hydrogen aims to secure a share of the billions in expected revenue. If it succeeds, the stock is a strong candidate for a revaluation. Meanwhile, Nel shareholders were hoping for further gains at the start of last week. However, the Norwegian company's quarterly results quickly brought the rally to an end.
Read
Commented by Lars Winter on October 13th, 2026 | 05:22 CEST
BioNxt, CrowdStrike and Shell: Three exciting stocks ahead of the next price surge
On the stock market, facts matter most. New study results, strong figures and solid operational records tend to attract investor attention and often drive share prices higher. These three stocks deserve a closer look: BioNxt Solutions is approaching its first human study, CrowdStrike has reported a record quarter, and Shell is benefiting from exceptionally high refining margins. Three very different stocks, each offering opportunities alongside distinct risks. We take a closer look at these compelling names in our stock check.
Read
Commented by Carsten Mainitz on October 12th, 2026 | 05:28 CEST
Don’t Miss Out! Cancer Research and Comeback Potential: Vidac Pharma, Bayer and Evotec in Focus!
New cancer therapies are targeting major medical breakthroughs. For investors, however, the key question is when scientific progress will begin to translate into rising share prices. Vidac Pharma is at a particularly exciting stage in its development. The company is awaiting crucial clinical trial data that could validate its innovative approach to cancer cell metabolism and mark a major milestone. Bayer is expanding its oncology business but must also contend with a range of challenges. Meanwhile, Evotec needs to prove it can turn its research, technology platforms, and strategic partnerships into profitable business opportunities while rebuilding lost investor confidence. Which developments could now trigger a revaluation of these three stocks?
Read
Commented by André Will-Laudien on October 9th, 2026 | 10:59 CEST
BioTech Rally 2027: Patents, Blockbusters and Biosimilars! The spotlight is on Bayer, Formycon, Evotec and Novo Nordisk
The storm in the pharmaceutical sector continues to gain momentum! Expiring patents and struggling healthcare systems are shaking up old, high-margin blockbuster drugs, as societal changes and government budget constraints shake the foundations of costly pharmaceutical development. As patents expire, many generic manufacturers find themselves in a race against time. Market shares are being reshuffled, heralding a new era of growth. Amid this dynamic rally, four well-known industry players are positioning themselves on different fronts to capitalize on the market shifts. After several difficult years, the Leverkusen-based pharmaceutical giant Bayer is fighting its way back with a completely revamped pipeline. Also in the fast lane is the German biosimilar hopeful from Munich, with its first products already on the market. At Hamburg-based drug discovery company Evotec, restructuring is still underway; the key driver is its state-of-the-art, AI-powered multivalent platform. Meanwhile, the Danish giant Novo Nordisk continues to ride the global obesity and diabetes wave, driving forward the next generation of its blockbuster drugs. Analysts do not have it easy, but there are plenty of opportunities for investors.
Read
Commented by Carsten Mainitz on October 9th, 2026 | 09:05 CEST
Weight-Loss Drugs 2.0: Can BioNxt and Merck Catch Up with Novo Nordisk and Eli Lilly? What About BioNTech?
The boom in weight-loss drugs is creating a billion-dollar market within the pharmaceutical industry, with an annual volume of USD 100 billion. Novo Nordisk and Eli Lilly are battling for dominance, while Merck is also entering the fray, albeit still in the early stages. BioNxt Solutions aims to deliver established active ingredients via a dissolvable film, targeting enormous potential with a comparatively low-risk approach. For BioNTech, a substantial cash reserve will determine how much time the company has to deliver its next growth spurt. Where does the greatest stock-market opportunity lie?
Read